Abiraterone acetate (AA) is a potent, selective androge (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA).

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety / Fabbri, M. A.; Cortesi, E.; Marchetti, Paolo; Santini, D.; Gamucci, T.; Angelini, F.; Longo, F.; Milano, Annalisa; Mancini, M. L.; Giuli, A.; Quadrini, S.; Sperduti, I.; Pellegrino, A.; Ratta, R.; Primi, F.; Chilelli, M. G.; Ruggeri, E. M.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - ELETTRONICO. - 51:3(2015), pp. 490-490. ((Intervento presentato al convegno European Cancer Congress tenutosi a Wien Austria [10.1016/S0959-8049(16)31363-6].

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety

E. Cortesi;MARCHETTI, PAOLO;D. Santini;MILANO, ANNALISA;
2015

Abstract

Abiraterone acetate (AA) is a potent, selective androge (CYP17) biosynthesis inhibitor, which showed to improve overall survival (HR = 0.646) in mCRPC patients progressing after docetaxel. In this retrospective analysis we assessed the safety and efficacy of AA in patients affected with mCRPC progressing after chemotherapy, treated in the normal clinical practice, in several Italian Oncologic Units, after the approval of the drug from the Italian Drug Agency (AIFA).
European Cancer Congress
.
04 Pubblicazione in atti di convegno::04c Atto di convegno in rivista
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety / Fabbri, M. A.; Cortesi, E.; Marchetti, Paolo; Santini, D.; Gamucci, T.; Angelini, F.; Longo, F.; Milano, Annalisa; Mancini, M. L.; Giuli, A.; Quadrini, S.; Sperduti, I.; Pellegrino, A.; Ratta, R.; Primi, F.; Chilelli, M. G.; Ruggeri, E. M.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - ELETTRONICO. - 51:3(2015), pp. 490-490. ((Intervento presentato al convegno European Cancer Congress tenutosi a Wien Austria [10.1016/S0959-8049(16)31363-6].
File allegati a questo prodotto
File Dimensione Formato  
Fabbri_ Abstract-2544-Abiraterone_2015.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 49.94 kB
Formato Adobe PDF
49.94 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/862090
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact